Allogeneic peripheral blood cell transplantation for hypereosinophilic syndrome with myelofibrosis

L Vazquez; D Caballero; C D Cañizo; C Lopez; R Hernandez; I Gonzalez; T Flores; J F San Miguel

doi:10.1038/sj.bmt.1702102

Allogeneic peripheral blood cell transplantation for hypereosinophilic syndrome with myelofibrosis

Bone Marrow Transplant. 2000 Jan;25(2):217-8. doi: 10.1038/sj.bmt.1702102.

Authors

L Vazquez¹, D Caballero, C D Cañizo, C Lopez, R Hernandez, I Gonzalez, T Flores, J F San Miguel

Affiliation

¹ Hematology Service, University Hospital of Salamanca; and Centro de Investigación del Cancer (CIC), University of Salamanca, CSIC, Spain.

PMID: 10673685
DOI: 10.1038/sj.bmt.1702102

Abstract

Patients with hypereosinophilic syndrome (HES) display a very heterogeneous clinical picture ranging from asymptomatic cases to very aggressive forms. We report a 38-year-old woman with progressive HES who developed severe myelofibrosis and was treated by allogeneic stem cell transplantation, using peripheral blood (PBSCT) instead of bone marrow as the source of progenitor cells, after conditioning with cytoxan and busulphan. To the best of our knowledge, this is the first case of HES with myelofibrosis treated with PBSCT. The patient remains alive 8 months post-PBSCT, and bone marrow fibrosis has significantly decreased following transplantation. Bone Marrow Transplantation (2000) 25, 217-218.

Publication types

Case Reports

MeSH terms

Adult
Female
Hematopoietic Stem Cell Transplantation*
Humans
Hypereosinophilic Syndrome / complications*
Hypereosinophilic Syndrome / pathology
Hypereosinophilic Syndrome / therapy*
Primary Myelofibrosis / complications*
Primary Myelofibrosis / pathology
Primary Myelofibrosis / therapy*
Transplantation Conditioning
Treatment Outcome